Guggenheim Cuts Illumina (NASDAQ:ILMN) Price Target to $150.00

Illumina (NASDAQ:ILMN) had its price target lowered by research analysts at Guggenheim from $170.00 to $150.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the life sciences company’s stock. Guggenheim’s price objective suggests a potential upside of 33.90% from the company’s previous close.

A number of other equities research analysts also recently commented on the stock. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Barclays lowered their target price on Illumina from $145.00 to $130.00 and set an “equal weight” rating for the company in a research note on Monday. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research note on Friday. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Stephens lifted their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Nine equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $162.25.

Illumina Trading Down 8.8 %

Illumina stock traded down $10.78 during trading on Friday, reaching $112.02. 2,215,078 shares of the company were exchanged, compared to its average volume of 1,842,704. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock’s 50 day simple moving average is $137.37 and its two-hundred day simple moving average is $135.34. Illumina has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a market capitalization of $17.77 billion, a P/E ratio of -11.30 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. On average, equities research analysts expect that Illumina will post 4.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Several large investors have recently modified their holdings of ILMN. WCM Investment Management LLC raised its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after acquiring an additional 27,618 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after purchasing an additional 48,018 shares during the last quarter. Primecap Management Co. CA boosted its position in Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after purchasing an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.